tbuckley/cabot-search huggingface dataset:
Abstract 455: Innovations in large scale liquid biopsy analysis and the Broad/IBM Cancer Resistance Project
Authors: Carrie Cibulskis, Brendan Blumenstiel, Matthew DeFelice, Mark Fleharty, Justin Abreu, Viktor Adalsteinsson, Laxmi Parida, Susanna Hamilton, Gad Getz, Niall Lennon
Journal: Cancer Research (2019)

Abstract Broad Genomics offers a comprehensive liquid biopsy sequencing platform designed to provide the optimal flexibility for conducting research studies in a broad range of applications including: biomarker discovery, treatment resistance monitoring, and clinical grade ctDNA profiling. By utilizing low cost, low coverage whole genome sequencing in conjunction with dual unique molecular indexed (UMI) libraries we can offer a range of analysis that allow researchers to select the most appropriate samples for whole exome profiling or for deeper coverage, higher sensitivity targeted gene panels. To date we have generated over 3000 liquid biopsy whole genome copy number profiles and purity estimates and are supporting driver projects including the Broad/IBM Cancer Resistance Project and Count Me In. The study design for the Broad/IBM effort takes advantage of the discovery potential of tissue-based sequencing combined with serial liquid biopsy analysis to elucidate resistance events by tracking clonal and subclonal populations in patient samples over time. Sourcing samples for this and other similar efforts is a major undertaking and a combination of methods for maximally broad and deep genomic profiling are required to assay patients throughout the course of care, as tumor fraction in blood fluctuates. Responding to this need, and other applications requiring increased sensitivity we have developed a high throughput, automated workflow to efficiently assay cfDNA samples with lower tumor content. Benchmarking data using healthy donor pooled cfDNA samples indicates our assay is capable of detecting &amp;gt; 90% of variants present at ~1% minor allele fraction with less than 1 false positive variant called per megabase. This established laboratory and analytic process forms the basis of our 2Mb, 400 gene CLIA targeted assay currently undergoing validation. Through this suite of products we hope to enable an expansion of cfDNA sequencing efforts in support of clinical and research applications. Early results from emerging studies utilizing this platform to be presented. Citation Format: Carrie Cibulskis, Brendan Blumenstiel, Matthew DeFelice, Mark Fleharty, Justin Abreu, Viktor Adalsteinsson, Laxmi Parida, Susanna Hamilton, Gad Getz, Niall Lennon. Innovations in large scale liquid biopsy analysis and the Broad/IBM Cancer Resistance Project [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 455.
RN, PA
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC).
Authors: U. Emmenegger, S. R. Berry, C. M. Booth, S. S. Sridhar, E. Winquist, N. Bandali, A. Chow, R. Kerbel, Y. Ko
Journal: Journal of Clinical Oncology (2011)

e15152 Background: TAX is the standard first-line chemotherapy for CRPC. However, a number of questions remain regarding the optimal use of TAX following maximal response. Aside from intermittent TAX, maintenance therapy with well-tolerated agents such as the mTOR inhibitor TEM could be one strategy to prolong treatment response and the chemotherapy-free interval, without significantly compromising quality of life. In fact, the mTOR pathway is involved in many aspects of CRPC, and mTOR inhibitors have demonstrated significant anti-CRPC activity in preclinical testing. Methods: CRPC pts eligible for this single-arm, multicenter phase II trial must have received between 6 to 8 cycles of first-line TAX (75 mg/m2 q3wks) with documented treatment response by PSA (>50% decline from baseline) or RECIST criteria. 30 pts will be enrolled and administered weekly TEM (25 mg iv x 4/cycle). The primary endpoint is time to treatment failure (TTF, by RECIST or symptomatic progression). Secondary endpoints include safety (NCI-CTCAE v3.0), quality of life (FACT-P, PPI), changes in PSA doubling time and time to PSA progression, objective tumor response rate (RECIST), and overall survival. We will also study correlative endpoints using plasma and peripheral blood mononuclear cells (i.e., markers of mTOR inhibition, of antiangiogenic TEM effects and of intratumoral hypoxia/acidosis, the latter as potential predictive markers). Results: 10 pts have been enrolled to date: mean age 68 (range 52 - 80), prior definitive local therapy (7) - radiation (6), prostatectomy (1), mean PSA at entry 99.28 (2.3 - 380.7), ECOG 0 (4) or 1 (6), prior cycles of TAX 6 (6) or 8 (4), sites of metastasis - bone (8), lymph nodes (4), visceral (3). 6 pts have been discontinued due to treatment failure after a mean of 5.3±1.9 cycles (range 3-8) - RECIST (1), symptomatic (2), combined (3). 4 pts are on cycle 1-2-8-9, respectively. TEM has been generally well tolerated without unexpected side-effects, but may have contributed to worsening lymphedema in 1 pt. Conclusions: TEM maintenance therapy in CRPC pts that have responded to first-line TAX is well tolerated and appears to result in meaningful TTF.
Results of CURE Trial for Acute Coronary Syndrome
Authors: M. Mitka
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abdominal Surgery
Authors: Claude E. Welch
Journal: New England Journal of Medicine (1964)

LiverInjuriesTraumatic injuries of the liver have been treated in the past by control of hemorrhage, debridement and adequate external drainage for bile and necrosed tissue. To these principles, Merendino et al.120 have proposed that a fourth be added — controlled biliary decompression by T-tube drainage of the common duct. This is wise because the normal pressure in the common duct is 30 cm. of water, and it can be increased to 40 cm. on coughing or after administration of drugs that produce spasm of the sphincter. Six cases are cited in support; in 1, a biliary fistula spontaneously . . .
REVIEWS
Journal: British Journal of Dermatology (1921)

British Journal of DermatologyVolume 33, Issue 11 p. 390-390 REVIEWS First published: November 1921 https://doi.org/10.1111/j.1365-2133.1921.tb09011.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article. Volume33, Issue11November 1921Pages 390-390 RelatedInformation
Cardiovascular surgery in Jehovah's Witnesses. Report of 542 operations without blood transfusion
Authors: D. A. Ott
Journal: JAMA (1977)

Jehovah's Witnesses who require operation represent a challenge to the physician because of the patients' refusal to accept blood transfusion. We report a 20-year experience with a consecutive series of 542 Jehovah's Witness patients ranging in age from 1 day to 89 years who underwent operation. Early mortality (within 30 days after operation) was 9.4%. In 362 patients requiring temporary cardiopulmonary bypass, early mortality was 10.7%. Mortality was 13.5% among 126 patients who had single- or double-valve replacement. The only deaths among patients who had aortic valve replacement or repair of a ventricular septal defect occurred in those who had some serious complication before operation. Preoperative or postoperative anemia was a contributing factor in 12 deaths, and loss of blood was the direct cause of three deaths. Cardiovascular operations can be performed safely without blood transfusion. (<i>JAMA</i>238:1256-1258, 1977)
Familial and metachronous malignant lymphoma: Absence of constitutional p53 mutations
Authors: Claudia Pötzsch, Hans‐Eckart Schaefer, Michael Lübbert
Journal: American Journal of Hematology (1999)

Familial and metachronous aggregations of malignant lymphoma are well-documented, but the molecular basis of a predisposition for development of lymphoma is as yet unclear. Malignant lymphomas have been described as part of the spectrum of neoplasias in Li-Fraumeni syndrome (LFS), which is associated with constitutional mutations of p53. However, p53 germline mutations have also, albeit less frequently, been described in patients not fitting the clinical definition of LFS. To clarify whether a genetic predisposition for lymphoma is associated with constitutional p53 mutations, DNA from normal blood lymphocytes of 12 lymphoma patients with a family history of lymphoma and/or with metachronous lymphoma (median age 37 years) was examined for mutations of p53 exons 4–8. One patient had four first-degree relatives with Hodgkin's disease, acute leukemia, and carcinomas, but the family history did not fulfill criteria of LFS. Four patients with Hodgkin's disease were diagnosed with metachronous non-Hodgkin's lymphoma as a second malignant neoplasm. No constitutional p53 mutations were detected in any of these patients, implying that outside the clinical spectrum of LFS, constitutional p53 mutations are rare in patients with lymphomas. Am. J. Hematol. 62:144–149, 1999. © 1999 Wiley-Liss, Inc.
<i>Neuropsychiatry and The War: A Bibliography with Abstracts</i>. Prepared Mabel Webster Brown, Librarian The National Committee for Mental Hygiene. Edited by Frankwood E. Williams, M. D., Associate Medical Director The National Committee for Mental Hygiene.(<i>New York: War Work Committee, The National Committee for Mental Hygiene, Inc., 1918</i>.)
Journal: American Journal of Psychiatry (1918)
Die zentrale Abstimmung der Sehsphäre.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract LB-276: The identification and characterization of prostate adenocarcinoma tumor initiating cells
Authors: Supreet Agarwal, Paul Hynes, Ross Lake, Lei Fang, Heather Tillman, Mike Beshiri, Keith Jansson, Wouter Karthaus, Philip Iaquinta, Charles Sawyers, Kathleen Kelly
Journal: Cancer Research (2016)

Abstract Primary prostate cancer is typically of luminal phenotype. However, little is known about the stem/progenitor properties of transformed luminal tumor cells as they fail to survive in culture. Using the organoid culture methodology, we show two distinct luminal progenitors in aggressive Pten/Tp53-null mouse model of prostate cancer. Not only did tumors contain previously described multipotent progenitors, but also a major population of committed luminal progenitors. The distinction between committed luminal and multipotent organoids was also evident in subcutaneous grafts as tumors of adenocarcinoma or multilineage histological phenotypes were observed, respectively. Moreover, using organoids we show that the self-renewing capacity of luminal-committed progenitors is a tumor-specific property, absent in benign luminal cells. Further, a significant fraction of luminal progenitors displayed resistance to in vivo castration as well as to androgen receptor inhibition ex vivo. Importantly, 3D organoid techniques have allowed us to relate our findings in humans as we can successfully grow similar luminal tumor populations from patient derived xenografts (PDXs) models of prostate cancer. In all, these data reveal two distinct luminal tumorigenic populations in mouse models of prostate cancer, providing insight into luminal tumor initiating cells in prostate cancer that can also influence response to therapy. Citation Format: Supreet Agarwal, Paul Hynes, Ross Lake, Lei Fang, Heather Tillman, Mike Beshiri, Keith Jansson, Wouter Karthaus, Philip Iaquinta, Charles Sawyers, Kathleen Kelly. The identification and characterization of prostate adenocarcinoma tumor initiating cells. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr LB-276.
Clinical crossroads: alcoholism and HIV infection
Authors: J. M. Zenilman
Journal: JAMA (1996)

<h3>In Reply.</h3> —We share the frustration of Drs Swanson, Cowen, Kattan, and Miles concerning the lack of randomized trial data for outcomes following different treatment strategies for localized prostate cancer. In the absence of such data, however, physicians and patients must still make clinical decisions. We designed our study to provide estimates of the maximum lost life expectancy a population of patients can anticipate if they choose conservative management for their localized disease. These data are critical to improving decision-analytic models.<sup>1</sup> Our study was not designed to evaluate the effectiveness of present-day surgery or radiation treatment. This requires a well-designed randomized trial such as PIVOT,<sup>1</sup>currently being conducted by several Veterans Affairs hospitals. Some physicians have criticized this trial on ethical grounds, while others have been reluctant to enroll patients because of their strong bias in favor of aggressive intervention. Our study documents that conservative management can achieve
Abstract 6246: Impact of Dysglycemia on Left Ventricular Functional Reserve in Acute Myocardial Infarction
Authors: Dan E Høfsten, Brian Løgstrup, Betina Nørager, Jacob E Møller, Kenneth Egstrup
Journal: Circulation (2008)

Background Abnormal glucose metabolism is common in patients with acute myocardial infarction (AMI), and is associated with excess morbidity and mortality. The reason for this is unclear but could be associated with an unfavourable effect on left ventricular (LV) functional reserve. Methods Low-dose dobutamine stress echocardiography (LDDE) was performed in 165 consecutive patients during admission for AMI. Peak early diastolic mitral annular velocity (E′), peak systolic mitral annular velocity (S′), and LV ejection fraction (LVEF) were measured at rest and during low dose dobutamine infusion. Glucose metabolism was assessed using an oral glucose tolerance test in patients without a previous diagnosis of diabetes. N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels were also measured. Results After adjustment for age, gender, hypertension, atrial fibrillation, peak troponin-T levels, diastolic blood pressure, heart rate, and body mass index, an inverse association between glucose metabolism and LV function was observed for E′ ( P =.005) and S′ ( P =.008) when measured during LDDE, but not when measured at rest (E′: P =.10; S′: P =.22). Neither rest nor stress LVEF was significantly associated with the degree of dysglycemia (rest: P =.67; LDDE: P =.19). All parameters measured during LDDE were significant predictors of NT-proBNP levels after adjustment for resting values (all variables: P &lt;.05). Conclusions In patients with a recent AMI, abnormal glucose metabolism is associated with impaired LV function during LDDE but not at rest; this is suggestive of depressed functional reserve.
Errors in Text, Figure, and End Matter
Journal: JAMA (2020)

Barnaby Edward Young, MB, BChir; Sean Wei Xiang Ong, MBBS; Shirin Kalimuddin, MPH; Jenny G. Low, MPH; Seow Yen Tan, MBBS; Jiashen Loh, MBBS; Oon-Tek Ng, MPH; Kalisvar Marimuthu, MBBS; Li Wei Ang, Msc; Tze Minn Mak, PhD; Sok Kiang Lau, PhD; Danielle E. Anderson, PhD; Kian Sing Chan, MBBS; Thean Yen Tan, MBBCh; Tong Yong Ng, MBBS; Lin Cui, PhD; Zubaidah Said, MSc; Lalitha Kurupatham, MPH; Mark I-Cheng Chen, PhD; Monica Chan, BMBS; Shawn Vasoo, MBBS; Lin-Fa Wang, PhD; Boon Huan Tan, PhD; Raymond Tzer Pin Lin, MBBS; Vernon Jian Ming Lee, PhD; Yee-Sin Leo, MPH; David Chien Lye, MBBS; for the Singapore 2019 Novel Coronavirus Outbreak Research Team
The Canadian military campaign of 1775-1776: medical problems and effects of disease
Authors: P. Cash
Journal: JAMA (1976)

During the opening year of the Revolution the newly formed Continental Army conducted two major campaigns. One, the Siege of Boston, basically a defensive operation, ended in a vital and exhilarating victory. The other, the offensive operation to secure Canada for the Whig cause, resulted in a disastrous and demoralizing defeat. In both instances medical factors strongly influenced the result. In this paper I explore the major medical aspects of the four phases of the Canadian campaign: Arnold's epic march through the Maine wilderness; Montgomery's offensive against St Johns, Chambly, and Montreal; their joint siege of Quebec; and the doleful retreat into upper New York state. I also suggest several pertinent comparisons with the medical practice and problems of the Continental Army besieging Boston.
A Phase II Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)
Authors: Christine Chen, Harminder Paul, Wei Xu, Vishal Kukreti, Suzanne Trudel, Ellen Wei, Zhi Hua Li, Joseph Brandwein, Mariela Pantoja, Chungyee Leung-Hagensteijn
Journal: Blood (2008)
Studien über die Permeabilität der Retina
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical Outcome of Cetuximab for Metastatic Colorectal Cancer Patients Harboring KRAS Codon61, KRAS Codon146, BRAF, NRAS or PIK3CA Mutations
Authors: K. Yamazaki, H. Bando, E. Shinozaki, T. Nishina, S. Kadowaki, S. Yuki, S. Kajiura, K. Tsuchihara, S. Fujii, T. Yamanaka, T. Yoshino
Journal: Annals of Oncology (2012)